Bone densitometry vendor Norland Medical Systems of White Plains,NY, has acquired rights to an ultrasound-based bone measurementsystem through an agreement with Vitel, a Texas company affiliatedwith the University of Texas Southwestern Medical Center in
Bone densitometry vendor Norland Medical Systems of White Plains,NY, has acquired rights to an ultrasound-based bone measurementsystem through an agreement with Vitel, a Texas company affiliatedwith the University of Texas Southwestern Medical Center in Dallas.
Vitel is developing bone measurement devices using a technologyit has licensed from the university called ultrasound criticalangle reflection (UCR). UCR technology can provide a quantitativeassessment of bone quality, according to Norland, making possiblean independent assessment of both cortical and trabecular bone.
Norland acquired exclusive worldwide rights to all productsdeveloped by Vitel and has agreed to make an equity investmentin Vitel. An ultrasound-based bone densitometry system would complementx-ray-based systems marketed by Norland and its Dove Medical Systemssubsidiary (SCAN 4/10/96).
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.